COMPANY
AMPEL BioSolutions
Timeline
- Trial start —: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE) source ↗
- Trial start Phase 4: A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE source ↗
- Trial start Phase 2: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect source ↗
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05845593 | Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE) | Not listed | Unknown status (ClinicalTrials.gov) | Dec 19, 2023 | Dec 10, 2024 (estimated) |
| NCT02598596 | Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect | Phase 2 | Completed | 2015-12 | Apr 13, 2020 (actual) |
| NCT03098823 | A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE | Phase 4 | Completed | Sep 12, 2017 | May 28, 2019 (actual) |